Table 2 of
Penha, Mol Vis 2012; 18:2608-2622. Table 2 of
Penha, Mol Vis 2012; 18:2608-2622.
Table 2. Effects of lens wear and intravitreal insulin, U0126 and Ly294002 injections, after 4 days of treatment, on refractive development and ocular dimensions.
| Injection/ Lens treatment | Saline | Insulin (0.3 µM) | U0126 (50 µM) | U0126+insulin (50 µM+0.3 µM) | Ly294002 (50 µM) | Ly294002+insulin (50 µM+0.3 µM) |
|---|---|---|---|---|---|---|
| 4 days WITHOUT LENSES (n=6) | ||||||
| Refraction [D] | +2.79±0.28 | +2.91±0.91 | +2.28±0.39 | +3.50±1.11 | +3.90±0.65 | +2.98±0.55 |
| ACD [mm] | 1.19±0.05 | 1.17±0.02 | 1.20±0.02 | 1.20±0.02 | 1.17±0.04 | 1.21±0.03 |
| LT [mm] | 2.21±0.04 | 2.17±0.02 | 2.10±0.01 | 2.13±0.03 | 2.10±0.04 | 2.17±0.03 |
| VCD [mm] | 5.19±0.05 | 5.06±0.09 | 5.20±0.03 | 5.09±0.06 | 5.20±0.05 | 5.09±0.08 |
| Axial length [mm] | 8.51±0.08 | 8.40±0.09 | 8.50±0.03 | 8.43±0.05 | 8.47±0.07 | 8.47±0.08 |
| 4 days with PLUS LENSES (n=6) | ||||||
| Refraction [D] | +6.25±0.79 | +0.49±0.81 | +3.88±2.07 | +3.00±2.02 | +6.40±1.64 | +0.61±1.46 |
| ACD [mm] | 1.02±0.05 | 1.18±0.05 | 1.06±0.05 | 1.21±0.07 | 1.15±0.06 | 1.24±0.09 |
| LT [mm] | 2.05±0.06 | 2.20±0.03 | 2.12±0.05 | 2.22±0.02 | 2.11±0.02 | 2.21±0.03 |
| VCD [mm] | 4.94±0.07 | 5.01±0.07 | 5.08±0.08 | 5.01±0.07 | 5.02±0.07 | 5.08±0.10 |
| Axial length [mm] | 8.01±0.09 | 8.39±0.10 | 8.26±0.11 | 8.44±0.14 | 8.28±0.10 | 8.53±0.17 |
| 4 days with MINUS LENSES (n=6) | ||||||
| Refraction [D] | −3.32±0.90 | −6.09±1.11 | −3.79±1.05 | −6.83±0.88 | −4.81±0.89 | −6.75±1.59 |
| ACD [mm] | 1.20±0.06 | 1.34±0.04 | 1.23±0.08 | 1.36±0.04 | 1.22±0.07 | 1.35±0.06 |
| LT [mm] | 2.14±0.04 | 2.25±0.05 | 2.15±0.04 | 2.30±0.06 | 2.18±0.08 | 2.11±0.04 |
| VCD [mm] | 5.48±0.10 | 5.45±0.07 | 5.51±0.09 | 5.50±0.12 | 5.48±0.13 | 5.55±0.10 |
| Axial length [mm] | 8.82±0.12 | 9.03±0.07 | 8.88±0.16 | 9.15±0.15 | 8.88±0.13 | 9.03±0.13 |